Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study

During the pandemic of COVID-19, which started in December 2019, hydroxychloroquine, the drug which was first introduced as antimalarial medication, was widely used to treat this new viral infection, and it was reported in the literature as a safe drug for use in patients with G6PD deficiency; here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Obeidat, Khaldun, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705928/
http://dx.doi.org/10.1159/000511688
Descripción
Sumario:During the pandemic of COVID-19, which started in December 2019, hydroxychloroquine, the drug which was first introduced as antimalarial medication, was widely used to treat this new viral infection, and it was reported in the literature as a safe drug for use in patients with G6PD deficiency; here, we report a 64-year-old male who was started on hydroxychloroquine as treatment for COVID-19 that led to hemolysis, and further investigation showed that the patient is deficient for glucose-6-phosphate dehydrogenase.

Ejemplares similares